Overcoming Cancers Resistant to HER-2 Antibodies
- 1st Edition, Volume 2 - July 15, 2024
- Imprint: Academic Press
- Editor: Benjamin Bonavida
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 1 6 4 0 8 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 6 7 3 8 - 0
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book a… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteOvercoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors.
This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
- Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance
- Offers potential underlying mechanisms by which cancer cells are either inherently resistant or become unresponsive to antibody treatment
- Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field
Cancer researchers, medical oncologists, clinicians, pharmacologists, translational investigators
- Cover image
- Title page
- Table of Contents
- Front Matter
- Copyright
- Aims and scope of series “Breaking tolerance to antibody-targeted therapies”
- About the Series Editor
- Aims and scope of the volume “Overcoming Cancers Resistant to HER-2 Antibodies”
- Preface “Overcoming Cancers Resistant to HER-2 Antibodies”
- Contributors
- Chapter 1 Resistance of breast cancer brain metastasis to trastuzumab therapy
- Abstract
- Conflict of interest
- Introduction
- Trastuzumab mechanism of action
- Notable mechanisms of HER2+ BCBM resistance to trastuzumab
- Emerging therapeutics for treatment of HER2+ BCBM
- Emerging strategies for crossing the blood-tumor barrier in trastuzumab-resistant BCBM
- Overview and efficacy of trastuzumab combination therapy
- Active clinical trials investigating brain metastases in HER2+ BC
- Conclusion
- References
- Chapter 2 Resistance of HER2-expressing breast cancer patients treated with trastuzumab: Underlying mechanisms of resistance and reversals
- Abstract
- Introduction
- Treatment options for breast cancer
- General features of HER2
- Treatment of HER2-expressing breast cancer
- Trastuzumab
- Mechanisms of resistance to trastuzumab treatment
- Trastuzumab-drug conjugates to overcome trastuzumab resistance
- Remarks and perspectives
- References
- Chapter 3 Understanding mechanisms of resistance to HER2-targeted therapies in HER2-positive breast cancer
- Abstract
- Conflict of interest
- Introduction
- HER2-targeted therapeutic effector mechanisms
- Resistance mechanisms to HER2-targeted therapies
- Conclusions
- References
- Chapter 4 Clinical implications and management strategies of resistance to anti-HER2 antibodies in breast cancer
- Abstract
- Conflict of interest
- Introduction
- HER2 signaling in MBC and targeted therapy
- Tackling HER2-positive MBC with targeted therapies and improved survival
- Emerging pathways of anti-HER2 therapy insensitivity and new therapeutic targets
- Anti-HER2 therapy resistance with clinical challenge and management strategies
- Future prospects
- Conclusion
- References
- Chapter 5 Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer
- Abstract
- Introduction
- Breast cancer resistances to conventional treatments
- HER2 overexpression and signaling
- The anti-HER2 mAb trastuzumab
- General trastuzumab resistance mechanisms
- Trastuzumab and antiapoptotic proteins
- Targeting antiapoptotic gene products to restore response to trastuzumab
- Combination of trastuzumab with anticancer immunotherapy
- Conclusions and future perspectives
- References
- Chapter 6 How does understanding epigenetics help circumvent HER-2 antibody resistance?
- Abstract
- Conflict of interest
- Introduction
- Molecular target therapy and anti-HER2 antibody mechanism of action and their combinations with other antineoplastic drugs
- Epigenetics and resistance to treatments: Mechanistic detailing
- Therapeutic antibodies and main clinical trials
- Impact on immune response and cell cycle
- Perspectives
- Conclusion
- References
- Chapter 7 Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance
- Abstract
- Introduction
- HER overview/HER2 expression
- Mechanisms of HER2 overexpression in cancer
- Activation of signaling pathways by HER2 overexpression and associated consequences
- Trastuzumab treatment of ovarian cancer
- Mechanisms of resistance
- Overcoming resistance to trastuzumab
- Discussion and future perspectives
- References
- Chapter 8 Clinical implications of resistance to anti-HER2 antibodies in breast cancer
- Abstract
- Conflict of interest
- Introduction
- Resistance to anti-HER2 monotherapies
- Impaired interaction of trastuzumab to HER2
- Lapatinib
- Trastuzumab-Emtansine drug conjugate
- Trastuzumab and Lapatinib combination
- Trastuzumab plus Pertuzumab
- Conclusion
- References
- Chapter 9 Highlights of current and future for the treatment of resistant HER2+ breast cancer to HER2-targeted therapies
- Abstract
- Introduction
- New therapeutic approaches to overcome resistance
- Harnessing the immune system
- Concluding remarks
- References
- Index
- Edition: 1
- Volume: 2
- Published: July 15, 2024
- No. of pages (Hardback): 228
- No. of pages (eBook): 250
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780128164082
- eBook ISBN: 9780128167380
BB
Benjamin Bonavida
Dr. Benjamin Bonavida is currently a Distinguished Research Professor at the University of California, Los Angeles (UCLA). He is affiliated with the Department of Microbiology, Immunology and Molecular Genetics, UCLA David Geffen School of Medicine, and the Jonsson Comprehensive Cancer Center at UCLA. His research career, thus far, has focused on investigations in the fields of basic immunochemistry and cancer immunobiology. His research investigations have ranged from the biochemical, molecular, and genetic mechanisms of cell-mediated killing and tumor cell resistance to chemo-immuno cytotoxic drugs. The reversal of tumor cell resistance was investigated by the use of various selected sensitizing agents based on molecular mechanisms of resistance. In these investigations, there was the newly characterized dysregulated NF-kB/ Snail/YY1/RKIP/PTEN loop in many cancers that was reported to regulate cell survival, proliferation, invasion, metastasis, and resistance. Emphasis was focused on the roles of the tumor suppressor Raf kinase inhibitor protein (RKIP) and the tumor promoter Yin Yang 1 (YY1) and the role of nitric oxide (NO) as a chemo-immuno-sensitizing factor. Many of the aforementioned studies are centered on the clinical challenging features of cancer patients’ failure to respond to both conventional and targeted therapies.
Dr. Bonavida has been active in the organization of regular sequential international miniconferences that are highly focused on the roles of YY1, RKIP, and nitric oxide in cancer and their potential therapeutic applications. Several books edited or coedited have been published. In addition, he is the Series Editor of books (over 20) published by Springer/Nature: Resistance to Anti-Cancer Targeted Therapeutics. In addition, he is presently the Series Editor of Three Series published by Elsevier/Academic Press on “Cancer Sensitizing Agents for Chemotherapy,” “Sensitizing Agents for Cancer Resistance to Cell Mediated Immunotherapy,” and “Breaking Tolerance to Anti-Cancer Antibody Immunotherapy.” He is the Editor-in-Chief of the Journal Critical Reviews in Oncogenesis, Editor-in-Chief of Onco Therapeutics, and Associate Editor of “Critical Reviews in Immunology.” Dr. Bonavida has published over 500 research publications and reviews in various scientific journals of high impact.
Affiliations and expertise
Distinguished Research Professor, Department of Microbiology, Immunology and Molecular Genetics, David Ge en School of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, California, USARead Overcoming Cancers Resistant to HER-2 Antibodies on ScienceDirect